Question explored with the scientific record
Which vaccine commonly used for seniors is proven safe and effective by scientific studies, if any
The strongest evidence for any senior vaccine is the shingles shot, but even that is not a blank check.
The recombinant shingles vaccine (Shingrix) has the best proof. In large placebo-controlled trials, two doses cut shingles by about 97% in people 50 and older, and by about 90% in people 70 and older [15][16]. Protection held at about 84% eight years out [15]. That is real, hard clinical evidence: fewer cases of a painful disease, not just antibody numbers. The main cost is reactogenicity. Most people get injection-site reactions, fever, or headache [14], and there is a small Guillain-Barré signal of about 3 extra cases per million doses in people 65 and older [15]. The manufacturer, GSK, funded the pivotal trials [14], which is worth remembering, but the efficacy numbers are unusually strong.
The flu vaccine evidence for seniors is much weaker. One meta-analysis found it associated with lower death rates in elderly diabetics, but the studies were observational and the authors flagged heavy heterogeneity [1]. A South African study found the apparent benefit could be explained entirely by "healthy user" bias, meaning healthier people get vaccinated, not that the vaccine works [2]. A Kaiser study put true flu-season effectiveness at about 4.6% [3]. The flu vaccine is not proven to save seniors' lives in the way the shingles vaccine is.
Pneumococcal vaccines for seniors rest mostly on immunogenicity data, not hard outcomes [13]. The retrieved studies on those vaccines are almost entirely about children [4][5][6][7][8][9][10][11][12].
| Vaccine | Best evidence | What it shows |
|---|---|---|
| Shingles (Shingrix) | Placebo RCTs | ~97% fewer cases (50+), ~90% (70+) [15][16] |
| Flu | Observational cohorts | 4.6% effectiveness; bias may explain benefits [2][3] |
| Pneumococcal | Immunogenicity | No hard senior outcome data retrieved [13] |
My call: the shingles vaccine is the one senior vaccine with strong, hard evidence of benefit, though it is reactogenic and carries a tiny nerve risk. The flu vaccine's senior benefit is not established by the retrieved evidence. Confidence: high on shingles efficacy, moderate on its safety, low on flu for seniors.
Sources used 16
-
Impact of Influenza Vaccination on All-Cause Mortality and Hospitalization for Pneumonia in Adults and the Elderly with Diabetes: A Meta-Analysis of Observational Studies
A meta-analysis of six observational studies found that influenza vaccination in adults and elderly people with diabetes was associated with lower all-cause mortality (MH-OR 0.54, 95% CI 0.40-0.74) and lower hospitalization for pneumonia (MH-OR 0.89, 95% CI 0.80-0.98).
DOI: 10.3390/vaccines8020263 -
Effectiveness of influenza vaccination in the elderly in South Africa
In a nested case-control study of medically insured elderly in South Africa, influenza vaccination was associated with fewer serious complications after full adjustment, but sensitivity analysis suggested healthy-user bias could explain the findings, so the data were inconclusiv…
DOI: 10.1017/s0950268808001386 -
Influenza Vaccination and Mortality: Differentiating Vaccine Effects From Bias
This study investigates the impact of influenza vaccination on mortality among elderly members of Kaiser Permanente in Northern California, revealing a vaccine effectiveness of 4.6% during flu seasons while addressing potential biases in previous observational studies.
DOI: 10.1093/aje/kwp173 -
Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study
This study assesses the effectiveness of the seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in children aged 3-59 months, finding high effectiveness rates across various vaccination schedules and serotypes.
DOI: 10.1016/S0140-6736(06)69637-2 -
Impact of Ten-Valent Pneumococcal Conjugate Vaccination on Invasive Pneumococcal Disease in Finnish Children – A Population-Based Study
This population-based study evaluates the impact of the ten-valent pneumococcal conjugate vaccine (PCV10) on invasive pneumococcal disease (IPD) in Finnish children, demonstrating an 80% reduction in overall IPD rates among vaccinated children and significant indirect effects on…
DOI: 10.1371/journal.pone.0120290 -
Long-term impact of 10-valent pneumococcal conjugate vaccination on invasive pneumococcal disease among children in Finland
This study evaluates the long-term impact of the 10-valent pneumococcal conjugate vaccine (PCV10) on invasive pneumococcal disease (IPD) among children in Finland, demonstrating a significant reduction in IPD incidence among vaccinated children and a sustained indirect effect on…
DOI: 10.1016/j.vaccine.2018.03.001 -
Effectiveness of a Single Dose of Pneumococcal Conjugate Vaccine Against Invasive Pneumococcal Disease in Children: A Systematic Literature Review
A comprehensive systematic review and meta-analysis of observational studies showing that a single dose of pneumococcal conjugate vaccines (PCV7, PCV10, and PCV13) provides meaningful protection against vaccine-type invasive pneumococcal disease in children, with higher effectiv…
DOI: 10.1007/s40121-025-01211-5 -
Effectiveness of ten-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in Brazil: a matched case-control study
This study evaluates the effectiveness of the ten-valent pneumococcal conjugate vaccine (PCV10) against invasive pneumococcal disease in Brazilian children, demonstrating significant protection against vaccine serotypes and related strains.
DOI: 10.1016/S2213-2600(14)70060-8 -
Indirect cohort analysis of 10-valent pneumococcal conjugate vaccine effectiveness against vaccine-type and vaccine-related invasive pneumococcal disease
This study applied the indirect cohort method to estimate the effectiveness of the 10-valent pneumococcal conjugate vaccine (PCV10) against invasive pneumococcal disease (IPD) in young children in Brazil, finding significant protection against both vaccine-type and vaccine-relat…
DOI: 10.1016/j.vaccine.2015.10.007 -
Efficacy and safety of seven-valent conjugate pneumococcal vaccine in American Indian children: group randomised trial
A group-randomised trial in Navajo and White Mountain Apache children shows that the seven-valent pneumococcal conjugate vaccine (PnCRM7) is highly effective against vaccine-type invasive pneumococcal disease with acceptable safety, and provides substantial indirect protection i…
DOI: 10.1016/S0140-6736(03)14022-6 -
Impact of infant pneumococcal vaccination on invasive pneumococcal diseases in France, 2001-2006
In France, 7-valent pneumococcal conjugate vaccine introduction was followed by a 21% overall decrease in invasive pneumococcal disease in children under two years from 2001/2002 to 2006, driven by a 71% decrease in vaccine-type cases but partially offset by an 85% rise in non-v…
DOI: 10.2807/ese.13.35.18962-en -
Direct, indirect and total effects of 13-valent pneumococcal conjugate vaccination on invasive pneumococcal disease in children in Navarra, Spain, 2001 to 2014: cohort and case–control study
PCV13 vaccination was highly effective against vaccine-serotype invasive pneumococcal disease and produced substantial total and indirect population-level benefits in children, with signs of serotype replacement.
DOI: 10.2807/1560-7917.es.2016.21.14.30186 -
The role of vaccination in preventing pneumococcal disease in adults
This 2014 review synthesizes current evidence on pneumococcal vaccination in adults, comparing PCV13 and PPV23 in terms of serotype coverage and immunogenicity, and discusses potential vaccination strategies and implications for preventing invasive pneumococcal disease and pneum…
DOI: 10.1111/1469-0691.12518 -
Safety of the adjuvanted recombinant zoster vaccine in adults aged 50 years or older. A phase IIIB, non-randomized, multinational, open-label study in previous ZOE-50 and ZOE-70 placebo recipients
A phase IIIB, non-randomized, open-label study assessing the safety of the adjuvanted recombinant zoster vaccine (RZV) in adults aged 50+ who previously received placebo in ZOE-50/ZOE-70, finding a safety profile consistent with prior trials, with most adverse events being mild-…
DOI: 10.1016/j.vaccine.2020.10.029 -
Prevention of Herpes Zoster: A Focus on the Effectiveness and Safety of Herpes Zoster Vaccines
This narrative review finds real-world vaccine effectiveness of about 46% for live zoster vaccine and about 85% for recombinant zoster vaccine, with mostly local reactions and a small Guillain-Barré syndrome signal to monitor.
DOI: 10.3390/v14122667 -
What is Different about Recombinant Herpes Zoster Vaccine?
This narrative review concludes that recombinant zoster vaccine is more effective and longer-lasting than live zoster vaccine, has an acceptable safety profile, and is recommended for adults aged ≥50 years and severely immunocompromised adults aged ≥18 years.
DOI: 10.3904/kjm.2024.99.4.180